natgillin/translations-raw huggingface dataset:
This may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent the development of macular oedema) after your operation.
To može biti do 3 tjedna (za sprječavanje i olakšavanje boli u oku i upale) ili 60 dana (za sprječavanje razvoja makularnog edema) nakon operacije.
5 ml round low density polyethylene bottle with a dispensing plug and white polypropylene screw cap containing 5 ml suspension.
Okrugla bočica od polietilena niske gustoće volumena 5 ml, s nastavkom za kapanje i bijelim polipropilenskim zatvaračem s navojem koja sadrži 5 ml suspenzije.
NEVANAC can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.
NEVANAC može utjecati na druge lijekove ili drugi lijekovi koje uzimate mogu utjecati na djelovanje NEVANAC-a, uključujući druge kapi za oko za liječenje povišenog očnog tlaka.
This may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent the development of macular oedema and to improve vision) after your operation.
To može biti do 3 tjedna (za sprječavanje i olakšavanje boli u oku i upale) ili 60 dana (za sprječavanje razvoja makularnog edema i poboljšanje vida) nakon operacije.
Nepafenac and amfenac were not quantifiable in the urine.
Količine nepafenaka i amfenaka nisu se mogle mjeriti u mokraći.
Wearing contact lenses is not recommended after cataract surgery.
Nošenje kontaktih leća ne preporučuje se nakon operacije mrene.
More patients treated with NEVANAC achieved a 15 letter improvement in BCVA compared to vehicle patients, 56.8% compared to 41.9%.
Više bolesnika liječenih s NEVANAC-om postiglo je poboljšanje od 15 slova u BCVA u usporedbi s bolesnicima koji su primali podlogu lijeka, 56,8% u usporedbi s 41,9%, p=0,019.
Do not use NEVANAC - if you are allergic to nepafenac or any of the other ingredients of this medicine (listed in section 6), - if you are allergic to other nonsteroidal anti-inflammatory drugs (NSAID) - if you have experienced asthma, skin allergy, or intense inflammation in your nose when using other NSAIDs.
Nemojte primjenjivati NEVANAC - ako ste alergični na nepafenak ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.), - ako ste alergični na druge nesteroidne protuupalne lijekove (NSAIL) - ako ste imali astmu, kožnu alergiju, ili jaku upalu u nosu kada ste koristili druge NSAIL-e.
Topical NSAIDs should be used with caution in these patients.
U tih bolesnika valja oprezno primjenjivati topikalne NSAIL-e.
Ocular adverse reactions in diabetic patients may occur at a higher frequency than observed in the general population (see section 4.4).
Nuspojave na oku mogu se javljati s većom učestalosti kod bolesnika s dijabetesom, u odnosu na opću populaciju (vidjeti dio 4.4).
In these studies in which patients were dosed daily beginning one day prior to cataract surgery, continued on the day of surgery and for the first 14 days of the postoperative period, NEVANAC 3 mg/ml eye drops, suspension demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.
U ovim ispitivanjima u kojima su bolesnicima primjenjivane dnevne doze počevši jedan dan prije operacije katarakte, nastavljane na dan operacije i tijekom prvih 14 dana postoperativnog perioda, NEVANAC 3 mg/ml kapi za oko, suspenzija pokazao je superiornu kliničku djelotvornost u usporedbi s podlogom lijeka u liječenju postoperativne boli i upale.
Clinical trial experience for the long-term use of NEVANAC for the prevention of macular oedema post cataract surgery in diabetic patients is limited.
Iskustvo kliničkih ispitivanja dugotrajne primjene NEVANAC-a za prevenciju makularnog edema nakon operacije katarakte je ograničeno.
In these studies, study medication was initiated the day prior to surgery, continued on the day of surgery and for up to 2-4 weeks of the postoperative period.
U tim se ispitivanjima započelo s primjenom ispitivanog lijeka jedan dan prije kirurškog zahvata, nastavilo na dan operacije te još do 2-4 tjedna tijekom postoperativnog perioda.
After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug.
Nakon topikalnog doziranja u oko, nepafenak penetrira kroz rožnicu i hidrolaze ga u očnom tkivu pretvaraju u amfenak, nesteroidni protuupalni lijek.
Do not use a double dose to make up for a missed dose.
Nemojte uzeti dvostruku dozu kako biste nadoknadili propuštenu dozu.
Patients should be instructed to avoid sunlight during treatment with NEVANAC.
Bolesnike je potrebno uputiti da tijekom liječenja s lijekom NEVANAC izbjegavaju sunčevo svjetlo.
In 1 double-masked, randomised vehicle-controlled study, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (16.7%) compared to patients treated with NEVANAC (3.2%).
U 1 dvostruko maskiranom, randomiziranom, podlogom lijeka kontroliranom ispitivanju, provedenom u bolesnika s dijabetičkom retinopatijom, značajno veći postotak bolesnika u grupi s podlogom lijeka razvio je makularni edem (16,7%) u usporedbi s bolesnicima liječenim NEVANAC-om (3,2%).
This medicine contains 0.25 mg benzalkonium chloride in each 5 ml which is equivalent to 0.05 mg/ml.
Ovaj lijek sadrži 0,25 mg benzalkonijevog klorida u svakih 5 ml, što odgovara 0,05 mg/ml.
This medicine contains 0.15 mg benzalkonium chloride in each 3 ml which is equivalent to 0.05 mg/ml.
Ovaj lijek sadrži 0,15 mg benzalkonijevog klorida u svakih 3 ml, što odgovara 0,05 mg/ml.
The majority of hydrolytic conversion is in the retina/choroid followed by the iris/ciliary body and cornea, consistent with the degree of vascularised tissue.
Veći dio hidrolitičke konverzije lijeka odvija se u mrežnici/žilnici, nakon toga u šarenici/cilijarnom tijelu i rožnici, što je sukladno stupnju prokrvljenosti tkiva.
Round or oval low density polyethylene bottle with a dispensing plug and white polypropylene screw cap containing 3 ml suspension.
Okrugla ili ovalna bočica od polietilena niske gustoće s nastavkom za kapanje i bijelim polipropilenskim zatvaračem s navojem koja sadrži 3 ml suspenzije.
A significantly higher percentage of patients in the NEVANAC group reported no ocular pain following cataract surgery compared to those in the vehicle group.
Značajno veći postotak bolesnika u skupini koja je primala NEVANAC izvijestio je da nakon operacije katarakte nema boli u usporedbi s onima u skupini koja je primala podlogu.
Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
Istodobna primjena topikalnih NSAIL-a i topikalnih steroida može povećati mogućnost razvoja poteškoća sa zacjeljivanjem.
Some patients received NEVANAC 3 mg/ml eye drops, suspension for up to 21 days post operation.
Neki bolesnici su primali NEVANAC 3 mg/ml kapi za oko, suspenziju do 21 dan nakon operacije.
Treatment can be extended to the first 3 weeks of the postoperative period, as directed by the clinician.
Liječenje se može produžiti na prva 3 tjedna nakon operacije, prema uputama liječnika.
The mean steady-state plasma Cmax for nepafenac and for amfenac were 0.847 ± 0.269 ng/ml and 1.13 ± 0.491 ng/ml, respectively, following ocular administration.
Srednje vrijednosti plazmatske Cmax u stanju dinamičke ravnoteže za nepafenak i za amfenak bile su 0,847±0,269 ng/ml, odnosno 1,13±0,491 ng/ml, nakon okularne primjene.
The other reported adverse reactions were corneal epithelium defect and allergic dermatitis which occurred in 1% and 0.5% of patients, respectively both adverse reactions with a frequency category of uncommon.
Ostale zabilježene nuspojave bile su defekt epitela rožnice i alergijski dermatitis, a koje su se pojavile u 1% odnosno 0,5% bolesnika, obje nuspojave unutar kategorije učestalosti manje često.
Four studies (two in diabetic patients and two in non-diabetic patients) were conducted to assess the efficacy and safety of NEVANAC for the prevention of postoperative macular oedema associated with cataract surgery.
Provedena su četiri ispitivanja (dva kod bolesnika s dijabetesom i dva kod bolesnika bez dijabetesa) za ocjenu djelotvornosti i sigurnosti NEVANAC-a za prevenciju postoperativnog makularnog edema povezanog s operacijom katarakte.
In both double-masked, randomised vehicle-controlled studies, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (17.3% and 14.3%) compared to patients treated with NEVANAC 3 mg/ml (2.3% and 5.9%).
U oba dvostruko maskirana, randomizirana, podlogom lijeka kontrolirana ispitivanja, provedena u bolesnika s dijabetičkom retinopatijom, značajno veći postotak bolesnika u grupi s podlogom lijeka razvio je makularni edem (17,3% i 14,3%) u usporedbi s bolesnicima liječenim lijekom NEVANAC 3 mg/ml (2,3% i 5,9%).
In addition, in one of the two clinical trials, NEVANAC 3 mg/ml eye drops, suspension dosed once a day was non-inferior to NEVANAC 1 mg/ml eye drops, suspension dosed three times a day for the prevention and treatment of postoperative pain and inflammation following cataract surgery.
Dodatno, u jednom od dva klinička ispitivanja, NEVANAC 3 mg/ml kapi za oko, suspenzija dozirana jednom dnevno bila je neinferiorana u odnosu na NEVANAC 1 mg/ml kapi za oko, suspenziju doziranu tri puta dnevno za prevenciju i liječenje postoperativne boli i upale nakon operacije katarakte.
In one double-masked, randomised, vehicle and active-controlled study, patients treated with NEVANAC had significantly less inflammation than those treated with vehicle.
U jednom dvostruko maskiranom, randomiziranom ispitivanju koje je kontrolirano s podlogom lijeka i djelatnom tvari, bolesnici liječeni NEVANAC-om imali su značajno manje upale od onih koji su primali podlogu lijeka.
In the two clinical studies involving 209 patients, diabetic patients were exposed to NEVANAC treatment for 60 days or greater for the prevention of macular oedema post cataract surgery.
U dva klinička ispitivanja koja su uključila 209 bolesnika, bolesnici s dijabetesom bili su izloženi liječenju NEVANAC-om 60 i više dana radi prevencije makularnog edema nakon operacije katarakte.
Prolonged use of topical NSAIDs may increase patient risk for occurrence and severity of corneal adverse reactions.
Prolongirana primjena topikalnih NSAIL-a može povećati rizik od pojave i težine nuspojava na rožnici.
In the two clinical studies involving 594 patients, diabetic patients were exposed to NEVANAC eye drops, suspension treatment for 90 days for the prevention of macular oedema post cataract surgery.
U dva klinička ispitivanja koja su uključila 594 bolesnika, bolesnici s dijabetesom bili su izloženi liječenju NEVANAC kapima za oko, suspenzijom tijekom 90 dana radi prevencije makularnog edema nakon operacije katarakte.
If more than one topical ophthalmic medicinal product is being used, the medicinal product must be administered at least 5 minutes apart.
Koristi li se više od jednog oftalmičkog lijeka za topikalnu primjenu, treba ih primjeniti u razmaku od najmanje 5 minuta.
The European Medicines Agency has waived the obligation to submit the results of studies with NEVANAC in all subsets of the paediatric population in prevention and treatment of post operative pain and inflammation associated with cataract surgery (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka NEVANAC-a u svim podskupinama pedijatrijske populacije u prevenciji i liječenju postoperativne boli i upale povezanih s operacijom katarakte (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
The mean steady-state plasma Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration.
Srednje vrijednosti plazmatske Cmax u stanju dinamičke ravnoteže za nepafenak i za amfenak bile su 0,310±0,104 ng/ml, odnosno 0,422±0,121 ng/ml, nakon okularne primjene.
Patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.
Bolesnici u kojih acetilsalicilatna kiselina ili drugi NSAIL-i uzrokuju napadaje astme, urtikariju ili akutni rinitis.
Write the date of opening on the bottle and carton label in the space provided.
Na naljepnici bočice i kutiji u predviđeni prostor napišite datum kada ste je otvorili.
It is unknown whether nepafenac is excreted in human milk.
Nije poznato izlučuje li se nepafenak u majčino mlijeko.
Treatment can be extended to the first 3 weeks of the postoperative period as directed by the clinician.
Liječenje se može produžiti na prva 3 tjedna nakon operacije prema uputama liječnika.
NEVANAC has not been studied in patients with hepatic disease or renal impairment.
NEVANAC nije ispitan u bolesnika s bolešću jetre ili oštećenjem bubrega.
Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
Redukcija rizika za postoperativni makularni edem povezan s operacijom katarakte kod bolesnika s dijabetesom
Patients with evidence of corneal epithelial breakdown including corneal perforation should immediately discontinue use of NEVANAC and should be monitored closely for corneal health (see section 4.4).
Bolesnici koji imaju znakove oštećenja epitela rožnice uključujući perforaciju rožnice, moraju odmah prekinuti primjenu NEVANAC-a, a stanje njihove rožnice mora biti pomno nadzirano (vidjeti dio 4.4).
- complicated eye surgery - repeated eye surgery within a short period of time - certain disorders of the surface of the eye, such as inflammation or dry eye - certain general disease, such as diabetes or rheumatoid arthritis
- komplicirani kirurški zahvat na oku - više kirurških zahvata na oku u kratkom vremenskom razdoblju - određene poremećaje površine oka, kao što su upala ili suho oko - određene opće bolesti, kao što su šećerna bolest ili reumatoidni artritis.
NEVANAC should not be used by women of child bearing potential not using contraception.
NEVANAC se ne smije primjenjivati kod žena repoduktivne dobi koje ne koriste kontracepciju.
Talk to your doctor, pharmacist or nurse before using NEVANAC: - if you bruise easily or have bleeding problems or have had them in the past - if you have any other eye disorder (e.g. an eye infection) or if you are using other medicines in the eye (especially topical steroids) - if you have diabetes - if you have rheumatoid arthritis - if you have had repeated eye surgery within a short period of time.
- ako ste skloni stvaranju masnica ili imate probleme s krvarenjima ili ste ih imali u prošlosti - ako imate neki drugi poremećaj na očima (npr. očnu infekciju), ili ako koristite druge lijekove za oči (osobito lokalne steroide) - ako imate šećernu bolest - ako imate reumatoidni artritis - ako ste unutar kratkog vremenskog razdoblja imali više kirurških zahvata na oku.
The European Medicines Agency has waived the obligation to submit the results of studies with NEVANAC in all subsets of the paediatric population in prevention and treatment of post operative pain and inflammation associated with cataract surgery and prevention of post surgical macular oedema (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka NEVANAC-a u svim podskupinama pedijatrijske populacije u prevenciji i liječenju postoperativne boli i upale povezanih s operacijom katarakte i prevencijom postoperativnog makularnog edema (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
How to use NEVANAC
Kako čuvati NEVANAC
In clinical studies involving 2314 patients receiving NEVANAC 1 mg/ml the most common adverse reactions were punctate keratitis, foreign body sensation and eyelid margin crusting which occurred in between 0.4% and 0.2% of patients.
U kliničkim ispitivanjima koja su uključila 2314 bolesnika koji su primali NEVANAC 1 mg/ml najučestalije nuspojave bile su punktiformni keratitis, osjećaj stranog tijela i stvaranje krusti na rubu vjeđe što je zabilježeno kod između 0,4% i 0,2% bolesnika.
The other most frequently reported adverse reactions were keratitis and foreign body sensation in eyes which occurred in 0.5% and 0.3% of patients, respectively both adverse reactions with a frequency category of uncommon.
Ostale najčešće zabilježene nuspojave bile su keratitis i osjećaj stranog tijela u oku, a koje su se pojavile u 0,5% odnosno 0,3% bolesnika, obje nuspojave unutar kategorije učestalosti manje često.
Following one drop of NEVANAC 3 mg/ml eye drops, suspension in both eyes once daily for four days, low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours post-dose, respectively.
Nakon doziranja NEVANAC 3 mg/ml kapi za oko, suspenzija u oba oka jedanputa na dan tijekom 4 dana, u većine su ispitanika zapažene niske, no mjerljive plazmatske koncentracije nepafenaka i amfenaka 2, odnosno 3 sata nakon doziranja.
NEVANAC is to be used by adults: - to prevent and relieve eye pain and inflammation following cataract surgery on the eye - to reduce the risk of macular oedema (swelling in the back of the eye) following cataract surgery on the eye in diabetic patients.
NEVANAC se koristi u odraslih osoba: - za sprječavanje i ublažavanje boli u oku i upale nakon operacije mrene na oku - za smanjenje rizika od makularnog edema (oticanje u pozadini oka) nakon operacije mrene na oku kod bolesnika sa šećernom bolesti.
From post-marketing experience with NEVANAC 1 mg/ml eye drops, suspension, cases reporting corneal epithelium defect/disorder have been identified.
Kroz iskustvo nakon stavljanja lijeka NEVANAC 1 mg/ml kapi za oko, suspenzija, u promet, zabilježeni su slučajevi defekta/poremećaja epitela rožnice.
Once-daily dosing with NEVANAC 3 mg/ml eye drops, suspension provides the same total daily dose of nepafenac as three-times-daily dosing with NEVANAC 1 mg/ml eye drops, suspension.
Doziranje jednom dnevno s NEVANAC 3 mg/ml kapima za oko, suspenzijom pruža istu ukupnu dnevnu dozu nepafenaka kao i doziranje tri puta dnevno s NEVANAC 1 mg/ml kapima za oko, suspenzijom.
The preservative in NEVANAC, benzalkonium chloride, may be absorbed by soft contact lenses and may change the colour of the contact lenses.
Konzervans u lijeku NEVANAC, benzalkonijev klorid, mogu apsorbirati meke kontaktne leće zbog čega se može promijeniti njihova boja.
- The other ingredients are benzalkonium chloride (see section 2), carbomer, disodium edetate, mannitol, purified water, sodium-chloride and tyloxapol.
• Drugi sastojci su benzalkonijev klorid (vidjeti dio 2), karbomer, dinatrijev edetat, manitol, pročišćena voda, natrijev klorid i tiloksapol.
Patients with renal or hepatic impairment
Bolesnici s oštećenjem bubrega i jetre
NEVANAC contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.
NEVANAC sadrži benzalkonijev klorid koji može izazvati iritaciju i za kojeg se zna da može promijeniti boju mekih kontaktnih leća.
Two studies in diabetic patients were conducted to assess the efficacy and safety of NEVANAC 3 mg/ml eye drops, suspension dosed once a day for the prevention of postoperative macular oedema associated with cataract surgery.
Provedena su dva ispitivanja kod bolesnika s dijabetesom za ocjenu djelotvornosti i sigurnosti NEVANAC 3 mg/ml kapi za oko, suspenzije dozirane jednom dnevno za prevenciju postoperativnog makularnog edema povezanog s operacijom katarakte.
Following 3 times daily dosing of NEVANAC eye drops in both eyes, low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours post-dose, respectively.
Nakon doziranja NEVANAC kapi za oko u oba oka tri puta na dan, u većine su ispitanika zapažene niske, no mjerljive plazmatske koncentracije nepafenaka i amfenaka 2, odnosno 3 sata nakon doziranja.
Do not use more than one drop in the affected eye(s).
U zahvaćeno oko(oči) ne ukapavajte više od jedne kapi.
Patients treated with NEVANAC were less likely to have ocular pain and measurable signs of inflammation (aqueous cells and flare) in the early postoperative period through to the end of treatment than those treated with its vehicle.
Kod bolesnika liječenih NEVANAC-om bila je manja vjerojatnost pojave boli u oku i mjerljivih znakova upale (stanice i zamućenje u očnoj vodici) u ranom postoperativnom periodu sve do kraja liječenja od onih liječenih s podlogom lijeka.
Additionally, NEVANAC was non-inferior to ketorolac 5 mg/ml in reducing inflammation and ocular pain, and was slightly more comfortable upon instillation.
Osim toga, u smanjenju upale i okularne boli NEVANAC nije bio inferioran u odnosu na ketorolak u dozi od 5 mg/ml, a po ukapavanju je bio malo ugodniji.
Uncommon: keratitis, punctate keratitis, corneal epithelium defect, foreign body sensation in eyes, eyelid margin crusting
Manje često: keratitis, punktiformni keratitis, defekt epitela rožnice, osjećaj stranoga tijela u očima, stvaranje krusti na rubu vjeđe
The most frequently reported adverse reaction was punctate keratitis which occurred in 1% of patients, resulting in a frequency category of common.
Najčešće zabilježena nuspojava bio je punktiformni keratitis koji se pojavio u 1% bolesnika, što je rezultiralo svrstavanjem unutar kategorije učestalosti često.
What NEVANAC looks like and contents of the pack NEVANAC eye drops, suspension (eye drops) is a liquid (light yellow to dark orange suspension) supplied in a plastic bottle with a screw cap. Each bottle may be placed in a pouch.
NEVANAC kapi za oko, suspenzija (kapi za oko) je tekućina (svijetložuta do tamnonarančasta suspenzija) dostupna u plastičnoj bočici sa zatvaračem s navojem.
If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku, ljekarniku ili medicinskoj sestri.
In two double-masked, randomised vehicle-controlled studies, patients treated with NEVANAC had significantly less inflammation (aqueous cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.
U dva dvostruko maskirana, randomizirana, podlogom lijeka kontrolirana ispitivanja, bolesnici, koji su liječeni NEVANAC-om imali su značajno manje upale (stanice i zamućenje u očnoj vodici) u početku postoperativnog razdoblja pa sve do kraja liječenja od onih koji su primali podlogu lijeka.
From post-marketing experience with NEVANAC, cases reporting corneal epithelium defect/disorder have been identified.
Kroz iskustvo nakon stavljanja lijeka NEVANAC u promet, zabilježeni su slučajevi defekta/poremećaja epitela rožnice.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of NEVANAC and should be monitored closely for corneal health.
Bolesnici u kojih se jave znakovi oštećenja rožnice, trebaju odmah prekinuti primjenu NEVANAC-a, a stanje njihove rožnice treba pomno nadzirati.
• Bring the bottle tip close to the eye. Do this in front of a mirror if it helps.
Ako Vam to pomaže, stanite pred ogledalo.
- Effects in the eye: eye surface inflammation with or without loss or damage of cells, foreign body sensation in the eyes, eyelid crusting or drooping.
• Nuspojave na oku: upala površine oka s ili bez gubitka ili oštećenja stanica, osjećaj stranoga tijela u očima, stvaranje krusti na vjeđi ili obješenost vjeđa.
No toxic effects are likely to occur in case of overdose with ocular use, nor in the event of accidental oral ingestion.
Malo je vjerojatno da će predoziranje kod okularne primjene, ili kod slučajne oralne ingestije uzrokovati toksično djelovanje.
The adverse reactions were obtained from clinical trials or post-marketing reports with NEVANAC 3 mg/ml eye drops, suspension and NEVANAC 1 mg/ml eye drops, suspension.
Nuspojave su zabilježene kroz klinička ispitivanja ili kroz iskustvo nakon stavljanja u promet lijeka NEVANAC 3 mg/ml kapi za oko, suspenzija i NEVANAC 1 mg/ml kapi za oko, suspenzija.
Do not use a double dose to make up for the 1 missed.
Nemojte uzeti dvostruku dozu kako biste nadoknadili propuštenu.